Get started
Author

Fengzhuo Cheng

ORCID: 0000-0003-1367-252X
Observed ORCID: 0000-0003-1367-252X
OpenAlex ID: A5000405171
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma
2023 · Lili Mao, Bin Lian, et al. · JAMA Oncology · 36
Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial
2025 · Yanjun Xu, Kaiyan Chen, et al. · The Lancet Oncology · 33
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
2025 · Yang-Si Li, Qitao Yu, et al. · Journal of Thoracic Oncology · 17
PDF
Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study
2024 · Xingxiang Pu, Gen Lin, et al. · EClinicalMedicine · 8
PDF
Sodium and Potassium Excretion of Schoolchildren and Relationship with Their Family Excretion in China
2021 · Yuan Li, Yuewen Sun, et al. · Nutrients · 7
PDF
Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies
2025 · Zhihao Lu, Guoping Sun, et al. · Cancer Immunology Immunotherapy · 5
First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China
2025 · Xue Hou, Chengzhi Zhou, et al. · EClinicalMedicine · 2
Road to Hierarchical Diabetes Management at Primary Care (ROADMAP) Study in China: Protocol for the Statistical Analysis of a Cluster Randomized Controlled Trial
2020 · Xian Li, Nadila Duolikun, et al. · JMIR Research Protocols · 1
PDF
Works count: 8
Citation count: 109
H-index: 5
I10-index: 3
Year
Topic
Type